Facilitated By

San Antonio Medical Foundation

Entyvio (Vedolizumab) Long-Term Safety Study: An international Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients with Ulcerative Colitis or Crohn's Disease

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Geneva Foundation
Research Start Date
Status
Active

This observational research study will involve approximately 5000 subjects with UC or CD in approximately 350 study centers located in North America and Europe. Study participants must be 18 years of age or older at the time of enrollment and will be either starting Vedolizumab or will be starting on another biologic medication for their disease. 20 of the patients will be from BAMC.

Collaborative Project
Clinical Care
Infectious Disease
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.